Comparison · NCT00308737-291304f7
Technosphere® Insulin vs Usual Care: FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Technosphere® Insulin vs Usual Care: FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care. Trial comparisons, record NCT00308737-291304f7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00308737-291304f7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0575 | 0.0428 | 0.0769 | wilson | |
| Risk in group 2 | 0.0328 | 0.0226 | 0.0473 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0248 | 0.00414 | 0.0466 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.76 | 1.09 | 2.82 | log | |
| Odds ratio, group 1 over group 2 | 1.8 | 1.1 | 2.95 | log | |
| Number needed to treat, for one more participant with the outcome on Technosphere® Insulin than on Usual Care | 40.4 | 21.5 | 242 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Technosphere® Insulin | Technosphere Insulin | 42 | 730 | OG000 |
| Group 2 | Usual Care | Usual care | 27 | 824 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care
- Description
- FEV1 decrease of ≥ 15% from Baseline value at last measurement
- Time frame
- Baseline to Month 24
- Population
- Intention to Treat (ITT)
Source ClinicalTrials.gov
Trial
- Title
- Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
- NCT number
- NCT00308737
- Phases
- PHASE3
- Conditions
- Diabetes, Type 1, Diabetes, Type 2
- Interventions
- Technosphere® Insulin Inhalation Powder, Usual Care
- Lead sponsor
- Mannkind Corporation
- Results first posted
- 2014-10-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00308737?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00308737-291304f7